Evidence map›Paper›PMID 39969763›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.

Mohammad Taghizadeh-Teymorloei, Vahid Jafarlou, Somaieh Matin, Mortaza Raeisi, Yousef Roosta, Sima Mansouri-Derakhshani, Abbas Ali Hosseinpour Feizi, Abbas Karimi

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mohammad Taghizadeh-TeymorloeiDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Golgasht St., Tabriz, 5166614756, East Azerbaijan, Iran.
Vahid JafarlouCancer Institute of Imam Khomeini Hospital, Tehran University of Medical Science, Tehran, Iran.
Somaieh MatinLung Diseases Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Mortaza RaeisiHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Yousef RoostaDepartment of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Sima Mansouri-DerakhshaniDepartment of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Genetics, Tabriz, Iran.
Abbas Ali Hosseinpour FeiziHematology-Oncology Research Center, Tabriz University of Medical Sciences, Tabriz Children's Hospital, Tabriz, Iran.
Abbas KarimiDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Golgasht St., Tabriz, 5166614756, East Azerbaijan, Iran. karimia@tbzmed.ac.ir.ORCID http://orcid.org/0000-0002-1172-8502

Funding

National Institute for Medical Research Development 4021131Tabriz University of Medical Sciences 71187
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) remains a significant global health challenge, characterized by high morbidity and mortality rates. This study explores the potential of Alu-based cell-free DNA (cfDNA) and specific PIWI-interacting RNAs (piRNAs) as innovative biomarkers for monitoring treatment responses in CRC patients.

methodsWe analyzed plasma samples from 70 CRC patients, equally divided between those undergoing chemotherapy and surgical interventions.

resultsOur findings reveal that certain piRNAs, particularly piRNA-823, piRNA-54265, and piRNA-1245, exhibit significant prognostic value, with notable expression changes observed in the chemotherapy group compared to the surgery group. Furthermore, the levels of ALU-based cfDNA fragments showed a marked decrease post-chemotherapy, suggesting their utility in assessing therapeutic efficacy.

conclusionsThis research underscores the importance of integrating these molecular tools particularly piRNA-823 and ALU-based cfDNA into clinical practice, potentially enhancing the management strategies for CRC patients and improving their outcomes.

Indexed as

Alu ElementsBiomarkers, TumorCell-Free Nucleic AcidsColorectal NeoplasmsRNA, Small InterferingAgedFemaleHumansMaleMiddle AgedPiwi-Interacting RNAPrognosisBiomarkers, TumorCell-Free Nucleic AcidsPiwi-Interacting RNARNA, Small InterferingALU-based cfDNAColorectal cancerPiRNAPrognosis

Identifiers

PMID39969763

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.